The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review

https://doi.org/10.17221/8762-VETMEDCitation:Landa L., Sulcova A., Gbelec P. (2016): The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Veterinarni Medicina, 61: 111-122.
download PDF
Cannabinoids/medical marijuana and their possible therapeutic use have received increased attention in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veterinary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific literature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary medicine.
References:
Alexander Stephen P.H., Benson Helen E., Faccenda Elena, Pawson Adam J., Sharman Joanna L., Spedding Michael, Peters John A., Harmar Anthony J. (2013): The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. British Journal of Pharmacology, 170, 1459-1581 https://doi.org/10.1111/bph.12445
 
Appendino Giovanni, Gibbons Simon, Giana Anna, Pagani Alberto, Grassi Gianpaolo, Stavri Michael, Smith Eileen, Rahman M. Mukhlesur (2008): Antibacterial Cannabinoids from Cannabis sativa : A Structure−Activity Study. Journal of Natural Products, 71, 1427-1430 https://doi.org/10.1021/np8002673
 
Batkai S. (2004): Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension. Circulation, 110, 1996-2002 https://doi.org/10.1161/01.CIR.0000143230.23252.D2
 
Battista Natalia, Di Tommaso Monia, Bari Monica, Maccarrone Mauro (2012): The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 6, - https://doi.org/10.3389/fnbeh.2012.00009
 
BISOGNO Tiziana, MELCK Dominique, BOBROV Mikhail Yu., GRETSKAYA Natalia M., BEZUGLOV Vladimir V., DE PETROCELLIS Luciano, DI MARZO Vincenzo (): N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 351, 817-824 https://doi.org/10.1042/bj3510817
 
Blake D. R. (2006): Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45, 50-52 https://doi.org/10.1093/rheumatology/kei183
 
Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C (2012): Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911–918.
 
Castillo Pablo E., Younts Thomas J., Chávez Andrés E., Hashimotodani Yuki (2012): Endocannabinoid Signaling and Synaptic Function. Neuron, 76, 70-81 https://doi.org/10.1016/j.neuron.2012.09.020
 
Cerrato S., Brazis P., della Valle M.F., Miolo A., Puigdemont A. (2010): Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Veterinary Immunology and Immunopathology, 133, 9-15 https://doi.org/10.1016/j.vetimm.2009.06.011
 
Cerrato Santiago, Brazis Pilar, della Valle Maria Federica, Miolo Alda, Petrosino Stefania, Marzo Vincenzo Di, Puigdemont Anna (2012): Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191, 377-382 https://doi.org/10.1016/j.tvjl.2011.04.002
 
Chambers Adam P, Koopmans Henry S, Pittman Quentin J, Sharkey Keith A (2006): AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology, 147, 109-116 https://doi.org/10.1038/sj.bjp.0706439
 
Chien Fred Y. (2003): Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in Monkeys. Archives of Ophthalmology, 121, 87- https://doi.org/10.1001/archopht.121.1.87
 
Contassot Emmanuel, Wilmotte Rick, Tenan Mirna, Belkouch Marie-Claude, Schnüriger Valérie, De Tribolet Nicolas, Bourkhardt Karim, Dietrich Pierre-Yves (): Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor-1. Journal of Neuropathology & Experimental Neurology, 63, 956-963 https://doi.org/10.1093/jnen/63.9.956
 
Croxford J Ludovic (2003): Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 17, 179-202 https://doi.org/10.2165/00023210-200317030-00004
 
Croxford JL, Yamamura T (2005): Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Journal of Neuroimmunology 166, 3–18.
 
Darmani NA (2001a): Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198–203.
 
Darmani NA (2001b): Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior 69, 239–249.
 
RODRIGUEZ de FONSECA F. (2004): THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 40, 2-14 https://doi.org/10.1093/alcalc/agh110
 
Devane W., Hanus L, Breuer A, Pertwee R., Stevenson L., Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949 https://doi.org/10.1126/science.1470919
 
Di Filippo C. (2003): Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, 75, 453-459 https://doi.org/10.1189/jlb.0703303
 
El-Remessy Azza B., Al-Shabrawey Mohamed, Khalifa Yousuf, Tsai Nai-Tse, Caldwell Ruth B., Liou Gregory I. (2006): Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. The American Journal of Pathology, 168, 235-244 https://doi.org/10.2353/ajpath.2006.050500
 
Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. (2008): Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 286, S97-S107 https://doi.org/10.1016/j.mce.2008.02.006
 
Figueiredo AS, Garcia-Crescioni HJ, Bulla SC, Ross MK, McIntosh C, Lunsford K, Bulla C (2013): Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line. Veterinary Medicine: Research and Reports 4, 31–34.
 
Fisar Zdenek (2009): Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviewse, 2, 51-75 https://doi.org/10.2174/1874473710902010051
 
Fischer Kristin M., Ward Daniel A., Hendrix Diane V. H. (2013): Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. American Journal of Veterinary Research, 74, 275-280 https://doi.org/10.2460/ajvr.74.2.275
 
Fitzgerald Kevin T., Bronstein Alvin C., Newquist Kristin L. (2013): Marijuana Poisoning. Topics in Companion Animal Medicine, 28, 8-12 https://doi.org/10.1053/j.tcam.2013.03.004
 
Gaffuri Anne-Lise, Ladarre Delphine, Lenkei Zsolt (2012): Type-1 Cannabinoid Receptor Signaling in Neuronal Development. Pharmacology, 90, 19-39 https://doi.org/10.1159/000339075
 
Galiegue Sylvaine, Mary Sophie, Marchand Jean, Dussossoy Danielle, Carriere Dominique, Carayon Pierre, Bouaboula Monsif, Shire David, Fur Gerard, Casellas Pierre (1995): Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. European Journal of Biochemistry, 232, 54-61 https://doi.org/10.1111/j.1432-1033.1995.tb20780.x
 
Gaoni Y., Mechoulam R. (1964): Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86, 1646-1647 https://doi.org/10.1021/ja01062a046
 
Giannini L., Nistri S., Mastroianni R., Cinci L., Vannacci A., Mariottini C., Passani M. B., Mannaioni P. F., Bani D., Masini E. (2008): Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. Journal of Cellular and Molecular Medicine, 12, 2381-2394 https://doi.org/10.1111/j.1582-4934.2008.00258.x
 
Girling S. J., Fraser M. A. (2011): Cannabis intoxication in three Green iguanas (Iguana iguana). Journal of Small Animal Practice, 52, 113-116 https://doi.org/10.1111/j.1748-5827.2010.01017.x
 
Grimaldi Claudia, Pisanti Simona, Laezza Chiara, Malfitano Anna Maria, Santoro Antonietta, Vitale Mario, Caruso Maria Gabriella, Notarnicola Maria, Iacuzzo Irma, Portella Giuseppe, Di Marzo Vincenzo, Bifulco Maurizio (2006): Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 312, 363-373 https://doi.org/10.1016/j.yexcr.2005.10.024
 
Gorji Ali, Ghadiri Maryam Khaleghi (2002): History of headache in medieval Persian medicine. The Lancet Neurology, 1, 510-515 https://doi.org/10.1016/S1474-4422(02)00226-0
 
Grotenhermen F (2006): Cannabinoids and the endocannabinoid system. Cannabinoids 1, 10–14.
 
Grotenhermen F, Muller-Vahl K (2012): The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International 109, 495–501.
 
Guzmán Manuel (2003): Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 3, 745-755 https://doi.org/10.1038/nrc1188
 
Han Sangdon, Thatte Jayant, Buzard Daniel J., Jones Robert M. (2013): Therapeutic Utility of Cannabinoid Receptor Type 2 (CB 2 ) Selective Agonists. Journal of Medicinal Chemistry, 56, 8224-8256 https://doi.org/10.1021/jm4005626
 
Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R. G., Ross R. A., Mechoulam R., Fride E. (1999): HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences, 96, 14228-14233 https://doi.org/10.1073/pnas.96.25.14228
 
Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., Kustanovich I., Mechoulam R. (2001): 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98, 3662-3665 https://doi.org/10.1073/pnas.061029898
 
Hayakawa Kazuhide, Mishima Kenichi, Fujiwara Michihiro (2010): Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals, 3, 2197-2212 https://doi.org/10.3390/ph3072197
 
Heifets Boris D., Castillo Pablo E. (2009): Endocannabinoid Signaling and Long-Term Synaptic Plasticity. Annual Review of Physiology, 71, 283-306 https://doi.org/10.1146/annurev.physiol.010908.163149
 
Hildebrandt Audrey L., Kelly-Sullivan Dawn M., Black Shawn C. (2003): Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125-132 https://doi.org/10.1016/S0014-2999(03)01343-8
 
Hill Andrew J., Williams Claire M., Whalley Benjamin J., Stephens Gary J. (2012): Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133, 79-97 https://doi.org/10.1016/j.pharmthera.2011.09.002
 
Izzo Angelo A., Borrelli Francesca, Capasso Raffaele, Di Marzo Vincenzo, Mechoulam Raphael (2009): Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30, 515-527 https://doi.org/10.1016/j.tips.2009.07.006
 
Jan Tong-Rong, Farraj Aimen K, Harkema Jack R, Kaminski Norbert E (2003): Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice ☆. Toxicology and Applied Pharmacology, 188, 24-35 https://doi.org/10.1016/S0041-008X(03)00010-3
 
Jones RT (2002): Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology 42, 58S–63S.
 
Kalant Harold (2001): Medicinal Use of Cannabis: History and Current Status. Pain Research and Management, 6, 80-91 https://doi.org/10.1155/2001/469629
 
Karst Matthias, Wippermann Sonja, Ahrens Jörg (2010): Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity. Drugs, 70, 2409-2438 https://doi.org/10.2165/11585260-000000000-00000
 
M. Keppel Hesselink Jan (2012): New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 5, 12-23 https://doi.org/10.2174/1876386301205010012
 
Kluger Benzi, Triolo Piera, Jones Wallace, Jankovic Joseph (2015): The therapeutic potential of cannabinoids for movement disorders. Movement Disorders, 30, 313-327 https://doi.org/10.1002/mds.26142
 
Kucerova Jana, Tabiova Katarina, Drago Filippo, Micale Vincenzo (2014): Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery, 9, 13-25 https://doi.org/10.2174/1574889809666140307115532
 
Landa L, Slais K, Machalova A, Sulcova A (2014a): The effect of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. Veterinarni Medicina 59, 88–94.
 
Landa L, Slais K, Machalova A, Sulcova A (2014b): Interaction of CB1 receptor agonist arachidonylcyclopropylamide with behavioural sensitisation to morphine in mice. Veterinarni Medicina 59, 307–314.
 
Lax Pedro, Esquiva Gema, Altavilla Cesare, Cuenca Nicolás (2014): Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Experimental Eye Research, 120, 175-185 https://doi.org/10.1016/j.exer.2014.01.019
 
Looney Andrea (2010): Oncology Pain in Veterinary Patients. Topics in Companion Animal Medicine, 25, 32-44 https://doi.org/10.1053/j.tcam.2009.10.008
 
LoVerme Jesse, La Rana Giovanna, Russo Roberto, Calignano Antonio, Piomelli Daniele (2005): The search for the palmitoylethanolamide receptor. Life Sciences, 77, 1685-1698 https://doi.org/10.1016/j.lfs.2005.05.012
 
Luongo Livio, Guida Francesca, Boccella Serena, Bellini Giulia, Gatta Luisa, Rossi Francesca, de Novellis Vito, Maione Sabatino (2013): Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice. CNS & Neurological Disorders - Drug Targets, 12, 45-54 https://doi.org/10.2174/1871527311312010009
 
Lynch Mary E., Campbell Fiona (2011): Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735-744 https://doi.org/10.1111/j.1365-2125.2011.03970.x
 
Lynch M. E., Ware Mark A. (2015): Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. Journal of Neuroimmune Pharmacology, 10, 293-301 https://doi.org/10.1007/s11481-015-9600-6
 
Lynch Mary E., Cesar-Rittenberg Paula, Hohmann Andrea G. (2014): A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain. Journal of Pain and Symptom Management, 47, 166-173 https://doi.org/10.1016/j.jpainsymman.2013.02.018
 
Maione Sabatino, Costa Barbara, Di Marzo Vincenzo (2013): Endocannabinoids: A unique opportunity to develop multitarget analgesics. PAIN®, 154, S87-S93 https://doi.org/10.1016/j.pain.2013.03.023
 
Massi Paola, Solinas Marta, Cinquina Valentina, Parolaro Daniela (2013): Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75, 303-312 https://doi.org/10.1111/j.1365-2125.2012.04298.x
 
Matsuda Lisa A., Lolait Stephen J., Brownstein Michael J., Young Alice C., Bonner Tom I. (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564 https://doi.org/10.1038/346561a0
 
McCarthy LE, Borison HL (1981): Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. Journal of Clinical Pharmacology 21, 30S–37S.
 
Mechoulam Raphael (2005): Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146, 913-915 https://doi.org/10.1038/sj.bjp.0706415
 
Mechoulam Raphael, Fride Ester, Di Marzo Vincenzo (1998): Endocannabinoids. European Journal of Pharmacology, 359, 1-18 https://doi.org/10.1016/S0014-2999(98)00649-9
 
Mechoulam Raphael, Hanuš Lumír O., Pertwee Roger, Howlett Allyn C. (): Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience, 15, 757-764 https://doi.org/10.1038/nrn3811
 
Mendizábal V E, Adler-Graschinsky E (2007): Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151, 427-440 https://doi.org/10.1038/sj.bjp.0707261
 
Meola Stacy D., Tearney Caitlin C., Haas Sharlee A., Hackett Timothy B., Mazzaferro Elisa M. (2012): Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care, 22, 690-696 https://doi.org/10.1111/j.1476-4431.2012.00818.x
 
Miller L. K., Devi L. A. (): The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications. Pharmacological Reviews, 63, 461-470 https://doi.org/10.1124/pr.110.003491
 
Muccioli Giulio G. (2010): Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today, 15, 474-483 https://doi.org/10.1016/j.drudis.2010.03.007
 
Mukhopadhyay Partha, Bátkai Sándor, Rajesh Mohanraj, Czifra Nora, Harvey-White Judith, Haskó György, Zsengeller Zsuzsanna, Gerard Norma P., Liaudet Lucas, Kunos George, Pacher Pál (2007): Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. Journal of the American College of Cardiology, 50, 528-536 https://doi.org/10.1016/j.jacc.2007.03.057
 
Munro Sean, Thomas Kerrie L., Abu-Shaar Muna (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65 https://doi.org/10.1038/365061a0
 
Nagarkatti Prakash, Pandey Rupal, Rieder Sadiye Amcaoglu, Hegde Venkatesh L, Nagarkatti Mitzi (2009): Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1, 1333-1349 https://doi.org/10.4155/fmc.09.93
 
Nolen RS (2013): With pet owners already using the drug as medicine, veterinarians need to join the debate. Journal of the American Veterinary Medical Association 242, 1604–1609.
 
Pacher P. (2006): The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58, 389-462 https://doi.org/10.1124/pr.58.3.2
 
Parker Linda A., Kwiatkowska Magdalena, Burton Page, Mechoulam Raphael (2004): Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology, 171, 156-161 https://doi.org/10.1007/s00213-003-1571-2
 
Pascual David, Goicoechea Carlos, Suardíaz Margarita, Martín María Isabel (2005): A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain, 118, 23-34 https://doi.org/10.1016/j.pain.2005.07.008
 
Pate David W., Järvinen Kristiina, Urtti Arto, Mahadevan Vaidyanath, Järvinen Tomi (1998): Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sciences, 63, 2181-2188 https://doi.org/10.1016/S0024-3205(98)00499-8
 
Pertwee Roger G. (1997): Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74, 129-180 https://doi.org/10.1016/S0163-7258(97)82001-3
 
Pertwee Roger G. (2005): The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal, 7, E625-E654 https://doi.org/10.1208/aapsj070364
 
Pertwee Roger G (2009): Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156, 397-411 https://doi.org/10.1111/j.1476-5381.2008.00048.x
 
Pertwee Roger G. (2014): Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proceedings of the Nutrition Society, 73, 96-105 https://doi.org/10.1017/S0029665113003649
 
Porcella Anna, Maxia Chiara, Gessa Gian Luigi, Pani Luca (2001): The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. European Journal of Neuroscience, 13, 409-412 https://doi.org/10.1046/j.0953-816X.2000.01401.x
 
Porter A. C. (): Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020-1024 https://doi.org/10.1124/jpet.301.3.1020
 
Presley BC, Jansen-Varnum SA, Logan BK (2013): Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review 25, 27–46.
 
Re G., Barbero R., Miolo A., Di Marzo V. (2007): Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal, 173, 21-30 https://doi.org/10.1016/j.tvjl.2005.10.003
 
ROBSON P. (): Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry, 178, 107-115 https://doi.org/10.1192/bjp.178.2.107
 
Rog D. J., Nurmikko T. J., Friede T., Young C. A. (): Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812-819 https://doi.org/10.1212/01.wnl.0000176753.45410.8b
 
Ross Ruth A (2003): Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology, 140, 790-801 https://doi.org/10.1038/sj.bjp.0705467
 
Russo Ethan (2008): Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, Volume 4, 245-259 https://doi.org/10.2147/TCRM.S1928
 
Sarfaraz S., Adhami V. M., Syed D. N., Afaq F., Mukhtar H. (2008): Cannabinoids for Cancer Treatment: Progress and Promise. Cancer Research, 68, 339-342 https://doi.org/10.1158/0008-5472.CAN-07-2785
 
Scarampella F., Abramo F., Noli C. (2001): Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology, 12, 29-39 https://doi.org/10.1046/j.1365-3164.2001.00214.x
 
Scheen André J., Paquot Nicolas (2009): Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 103-116 https://doi.org/10.1016/j.beem.2008.09.001
 
Serpell M., Ratcliffe S., Hovorka J., Schofield M., Taylor L., Lauder H., Ehler E. (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain, 18, 999-1012 https://doi.org/10.1002/j.1532-2149.2013.00445.x
 
Slais K., Landa L., Sulcova A. (2003): P.5.023 The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/exploratory behaviour and body weight in mice. European Neuropsychopharmacology, 13, S417- https://doi.org/10.1016/S0924-977X(03)92272-3
 
Slavic Svetlana, Lauer Dilyara, Sommerfeld Manuela, Kemnitz Ulrich Rudolf, Grzesiak Aleksandra, Trappiel Manuela, Thöne-Reineke Christa, Baulmann Johannes, Paulis Ludovit, Kappert Kai, Kintscher Ulrich, Unger Thomas, Kaschina Elena (2013): Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 91, 811-823 https://doi.org/10.1007/s00109-013-1034-0
 
Song ZH, Slowey CA (2000): Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. Journal of Pharmacology and Experimental Therapeutics 292, 136–139.
 
Stanley CP, Hind WH, O’Sullivan SE (2013): Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology 75, 313–322.
 
Steffens Sabine, Pacher Pál (2012): Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. British Journal of Pharmacology, 167, 313-323 https://doi.org/10.1111/j.1476-5381.2012.02042.x
 
Steffens Sabine, Veillard Niels R., Arnaud Claire, Pelli Graziano, Burger Fabienne, Staub Christian, Zimmer Andreas, Frossard Jean-Louis, Mach François (2005): Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434, 782-786 https://doi.org/10.1038/nature03389
 
SVIZENSKA I, DUBOVY P, SULCOVA A (2008): Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90, 501-511 https://doi.org/10.1016/j.pbb.2008.05.010
 
Tallett Amy J., Blundell John E., Rodgers John R. (2007): Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behavioural Pharmacology, 18, 591-600 https://doi.org/10.1097/FBP.0b013e3282eff0a9
 
Unschuld PU (1986): Medicine in China. A History of Pharmaceutics. University of California Press, Berkeley and Los Angele. 167 pp.
 
Van Sickle Marja D., Oland Lorraine D., Mackie Ken, Davison Joseph S., Sharkey Keith A. (): Δ 9 -Tetrahydrocannabinol selectively acts on CB 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. American Journal of Physiology - Gastrointestinal and Liver Physiology, 285, G566-G576 https://doi.org/10.1152/ajpgi.00113.2003
 
Van Sickle M. D. (2005): Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 310, 329-332 https://doi.org/10.1126/science.1115740
 
Velasco Guillermo, Sánchez Cristina, Guzmán Manuel (): Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 12, 436-444 https://doi.org/10.1038/nrc3247
 
Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., Gallily R. (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39, 143-151 https://doi.org/10.1080/08916930500356674
 
Weiss Lola, Zeira Michael, Reich Shoshana, Slavin Shimon, Raz Itamar, Mechoulam Raphael, Gallily Ruth (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54, 244-249 https://doi.org/10.1016/j.neuropharm.2007.06.029
 
Xiong W., Cui T., Cheng K., Yang F., Chen S.-R., Willenbring D., Guan Y., Pan H.-L., Ren K., Xu Y., Zhang L. (): Cannabinoids suppress inflammatory and neuropathic pain by targeting  3 glycine receptors. Journal of Experimental Medicine, 209, 1121-1134 https://doi.org/10.1084/jem.20120242
 
Zuardi Antonio Waldo (2006): History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria, 28, 153-157 https://doi.org/10.1590/S1516-44462006000200015
 
Zubrzycki M, Liebold A, Janecka A, Zubrzycka M (2014): A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and Pharmacology 65, 171–181.
 
Alexander Stephen P.H., Benson Helen E., Faccenda Elena, Pawson Adam J., Sharman Joanna L., Spedding Michael, Peters John A., Harmar Anthony J. (2013): The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. British Journal of Pharmacology, 170, 1459-1581 https://doi.org/10.1111/bph.12445
 
Appendino Giovanni, Gibbons Simon, Giana Anna, Pagani Alberto, Grassi Gianpaolo, Stavri Michael, Smith Eileen, Rahman M. Mukhlesur (2008): Antibacterial Cannabinoids from Cannabis sativa : A Structure−Activity Study. Journal of Natural Products, 71, 1427-1430 https://doi.org/10.1021/np8002673
 
Batkai S. (2004): Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension. Circulation, 110, 1996-2002 https://doi.org/10.1161/01.CIR.0000143230.23252.D2
 
Battista Natalia, Di Tommaso Monia, Bari Monica, Maccarrone Mauro (2012): The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 6, - https://doi.org/10.3389/fnbeh.2012.00009
 
BISOGNO Tiziana, MELCK Dominique, BOBROV Mikhail Yu., GRETSKAYA Natalia M., BEZUGLOV Vladimir V., DE PETROCELLIS Luciano, DI MARZO Vincenzo (): N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 351, 817-824 https://doi.org/10.1042/bj3510817
 
Blake D. R. (2006): Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45, 50-52 https://doi.org/10.1093/rheumatology/kei183
 
Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C (2012): Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911–918.
 
Castillo Pablo E., Younts Thomas J., Chávez Andrés E., Hashimotodani Yuki (2012): Endocannabinoid Signaling and Synaptic Function. Neuron, 76, 70-81 https://doi.org/10.1016/j.neuron.2012.09.020
 
Cerrato S., Brazis P., della Valle M.F., Miolo A., Puigdemont A. (2010): Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Veterinary Immunology and Immunopathology, 133, 9-15 https://doi.org/10.1016/j.vetimm.2009.06.011
 
Cerrato Santiago, Brazis Pilar, della Valle Maria Federica, Miolo Alda, Petrosino Stefania, Marzo Vincenzo Di, Puigdemont Anna (2012): Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191, 377-382 https://doi.org/10.1016/j.tvjl.2011.04.002
 
Chambers Adam P, Koopmans Henry S, Pittman Quentin J, Sharkey Keith A (2006): AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology, 147, 109-116 https://doi.org/10.1038/sj.bjp.0706439
 
Chien Fred Y. (2003): Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in Monkeys. Archives of Ophthalmology, 121, 87- https://doi.org/10.1001/archopht.121.1.87
 
Contassot Emmanuel, Wilmotte Rick, Tenan Mirna, Belkouch Marie-Claude, Schnüriger Valérie, De Tribolet Nicolas, Bourkhardt Karim, Dietrich Pierre-Yves (): Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor-1. Journal of Neuropathology & Experimental Neurology, 63, 956-963 https://doi.org/10.1093/jnen/63.9.956
 
Croxford J Ludovic (2003): Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 17, 179-202 https://doi.org/10.2165/00023210-200317030-00004
 
Croxford JL, Yamamura T (2005): Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Journal of Neuroimmunology 166, 3–18.
 
Darmani NA (2001a): Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198–203.
 
Darmani NA (2001b): Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior 69, 239–249.
 
RODRIGUEZ de FONSECA F. (2004): THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 40, 2-14 https://doi.org/10.1093/alcalc/agh110
 
Devane W., Hanus L, Breuer A, Pertwee R., Stevenson L., Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949 https://doi.org/10.1126/science.1470919
 
Di Filippo C. (2003): Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, 75, 453-459 https://doi.org/10.1189/jlb.0703303
 
El-Remessy Azza B., Al-Shabrawey Mohamed, Khalifa Yousuf, Tsai Nai-Tse, Caldwell Ruth B., Liou Gregory I. (2006): Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. The American Journal of Pathology, 168, 235-244 https://doi.org/10.2353/ajpath.2006.050500
 
Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. (2008): Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 286, S97-S107 https://doi.org/10.1016/j.mce.2008.02.006
 
Figueiredo AS, Garcia-Crescioni HJ, Bulla SC, Ross MK, McIntosh C, Lunsford K, Bulla C (2013): Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line. Veterinary Medicine: Research and Reports 4, 31–34.
 
Fisar Zdenek (2009): Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviewse, 2, 51-75 https://doi.org/10.2174/1874473710902010051
 
Fischer Kristin M., Ward Daniel A., Hendrix Diane V. H. (2013): Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. American Journal of Veterinary Research, 74, 275-280 https://doi.org/10.2460/ajvr.74.2.275
 
Fitzgerald Kevin T., Bronstein Alvin C., Newquist Kristin L. (2013): Marijuana Poisoning. Topics in Companion Animal Medicine, 28, 8-12 https://doi.org/10.1053/j.tcam.2013.03.004
 
Gaffuri Anne-Lise, Ladarre Delphine, Lenkei Zsolt (2012): Type-1 Cannabinoid Receptor Signaling in Neuronal Development. Pharmacology, 90, 19-39 https://doi.org/10.1159/000339075
 
Galiegue Sylvaine, Mary Sophie, Marchand Jean, Dussossoy Danielle, Carriere Dominique, Carayon Pierre, Bouaboula Monsif, Shire David, Fur Gerard, Casellas Pierre (1995): Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. European Journal of Biochemistry, 232, 54-61 https://doi.org/10.1111/j.1432-1033.1995.tb20780.x
 
Gaoni Y., Mechoulam R. (1964): Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86, 1646-1647 https://doi.org/10.1021/ja01062a046
 
Giannini L., Nistri S., Mastroianni R., Cinci L., Vannacci A., Mariottini C., Passani M. B., Mannaioni P. F., Bani D., Masini E. (2008): Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. Journal of Cellular and Molecular Medicine, 12, 2381-2394 https://doi.org/10.1111/j.1582-4934.2008.00258.x
 
Girling S. J., Fraser M. A. (2011): Cannabis intoxication in three Green iguanas (Iguana iguana). Journal of Small Animal Practice, 52, 113-116 https://doi.org/10.1111/j.1748-5827.2010.01017.x
 
Grimaldi Claudia, Pisanti Simona, Laezza Chiara, Malfitano Anna Maria, Santoro Antonietta, Vitale Mario, Caruso Maria Gabriella, Notarnicola Maria, Iacuzzo Irma, Portella Giuseppe, Di Marzo Vincenzo, Bifulco Maurizio (2006): Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 312, 363-373 https://doi.org/10.1016/j.yexcr.2005.10.024
 
Gorji Ali, Ghadiri Maryam Khaleghi (2002): History of headache in medieval Persian medicine. The Lancet Neurology, 1, 510-515 https://doi.org/10.1016/S1474-4422(02)00226-0
 
Grotenhermen F (2006): Cannabinoids and the endocannabinoid system. Cannabinoids 1, 10–14.
 
Grotenhermen F, Muller-Vahl K (2012): The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International 109, 495–501.
 
Guzmán Manuel (2003): Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 3, 745-755 https://doi.org/10.1038/nrc1188
 
Han Sangdon, Thatte Jayant, Buzard Daniel J., Jones Robert M. (2013): Therapeutic Utility of Cannabinoid Receptor Type 2 (CB 2 ) Selective Agonists. Journal of Medicinal Chemistry, 56, 8224-8256 https://doi.org/10.1021/jm4005626
 
Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R. G., Ross R. A., Mechoulam R., Fride E. (1999): HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences, 96, 14228-14233 https://doi.org/10.1073/pnas.96.25.14228
 
Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., Kustanovich I., Mechoulam R. (2001): 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98, 3662-3665 https://doi.org/10.1073/pnas.061029898
 
Hayakawa Kazuhide, Mishima Kenichi, Fujiwara Michihiro (2010): Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals, 3, 2197-2212 https://doi.org/10.3390/ph3072197
 
Heifets Boris D., Castillo Pablo E. (2009): Endocannabinoid Signaling and Long-Term Synaptic Plasticity. Annual Review of Physiology, 71, 283-306 https://doi.org/10.1146/annurev.physiol.010908.163149
 
Hildebrandt Audrey L., Kelly-Sullivan Dawn M., Black Shawn C. (2003): Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125-132 https://doi.org/10.1016/S0014-2999(03)01343-8
 
Hill Andrew J., Williams Claire M., Whalley Benjamin J., Stephens Gary J. (2012): Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133, 79-97 https://doi.org/10.1016/j.pharmthera.2011.09.002
 
Izzo Angelo A., Borrelli Francesca, Capasso Raffaele, Di Marzo Vincenzo, Mechoulam Raphael (2009): Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30, 515-527 https://doi.org/10.1016/j.tips.2009.07.006
 
Jan Tong-Rong, Farraj Aimen K, Harkema Jack R, Kaminski Norbert E (2003): Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice ☆. Toxicology and Applied Pharmacology, 188, 24-35 https://doi.org/10.1016/S0041-008X(03)00010-3
 
Jones RT (2002): Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology 42, 58S–63S.
 
Kalant Harold (2001): Medicinal Use of Cannabis: History and Current Status. Pain Research and Management, 6, 80-91 https://doi.org/10.1155/2001/469629
 
Karst Matthias, Wippermann Sonja, Ahrens Jörg (2010): Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity. Drugs, 70, 2409-2438 https://doi.org/10.2165/11585260-000000000-00000
 
M. Keppel Hesselink Jan (2012): New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 5, 12-23 https://doi.org/10.2174/1876386301205010012
 
Kluger Benzi, Triolo Piera, Jones Wallace, Jankovic Joseph (2015): The therapeutic potential of cannabinoids for movement disorders. Movement Disorders, 30, 313-327 https://doi.org/10.1002/mds.26142
 
Kucerova Jana, Tabiova Katarina, Drago Filippo, Micale Vincenzo (2014): Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery, 9, 13-25 https://doi.org/10.2174/1574889809666140307115532
 
Landa L, Slais K, Machalova A, Sulcova A (2014a): The effect of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. Veterinarni Medicina 59, 88–94.
 
Landa L, Slais K, Machalova A, Sulcova A (2014b): Interaction of CB1 receptor agonist arachidonylcyclopropylamide with behavioural sensitisation to morphine in mice. Veterinarni Medicina 59, 307–314.
 
Lax Pedro, Esquiva Gema, Altavilla Cesare, Cuenca Nicolás (2014): Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Experimental Eye Research, 120, 175-185 https://doi.org/10.1016/j.exer.2014.01.019
 
Looney Andrea (2010): Oncology Pain in Veterinary Patients. Topics in Companion Animal Medicine, 25, 32-44 https://doi.org/10.1053/j.tcam.2009.10.008
 
LoVerme Jesse, La Rana Giovanna, Russo Roberto, Calignano Antonio, Piomelli Daniele (2005): The search for the palmitoylethanolamide receptor. Life Sciences, 77, 1685-1698 https://doi.org/10.1016/j.lfs.2005.05.012
 
Luongo Livio, Guida Francesca, Boccella Serena, Bellini Giulia, Gatta Luisa, Rossi Francesca, de Novellis Vito, Maione Sabatino (2013): Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice. CNS & Neurological Disorders - Drug Targets, 12, 45-54 https://doi.org/10.2174/1871527311312010009
 
Lynch Mary E., Campbell Fiona (2011): Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735-744 https://doi.org/10.1111/j.1365-2125.2011.03970.x
 
Lynch M. E., Ware Mark A. (2015): Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. Journal of Neuroimmune Pharmacology, 10, 293-301 https://doi.org/10.1007/s11481-015-9600-6
 
Lynch Mary E., Cesar-Rittenberg Paula, Hohmann Andrea G. (2014): A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain. Journal of Pain and Symptom Management, 47, 166-173 https://doi.org/10.1016/j.jpainsymman.2013.02.018
 
Maione Sabatino, Costa Barbara, Di Marzo Vincenzo (2013): Endocannabinoids: A unique opportunity to develop multitarget analgesics. PAIN®, 154, S87-S93 https://doi.org/10.1016/j.pain.2013.03.023
 
Massi Paola, Solinas Marta, Cinquina Valentina, Parolaro Daniela (2013): Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75, 303-312 https://doi.org/10.1111/j.1365-2125.2012.04298.x
 
Matsuda Lisa A., Lolait Stephen J., Brownstein Michael J., Young Alice C., Bonner Tom I. (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564 https://doi.org/10.1038/346561a0
 
McCarthy LE, Borison HL (1981): Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. Journal of Clinical Pharmacology 21, 30S–37S.
 
Mechoulam Raphael (2005): Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146, 913-915 https://doi.org/10.1038/sj.bjp.0706415
 
Mechoulam Raphael, Fride Ester, Di Marzo Vincenzo (1998): Endocannabinoids. European Journal of Pharmacology, 359, 1-18 https://doi.org/10.1016/S0014-2999(98)00649-9
 
Mechoulam Raphael, Hanuš Lumír O., Pertwee Roger, Howlett Allyn C. (): Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience, 15, 757-764 https://doi.org/10.1038/nrn3811
 
Mendizábal V E, Adler-Graschinsky E (2007): Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151, 427-440 https://doi.org/10.1038/sj.bjp.0707261
 
Meola Stacy D., Tearney Caitlin C., Haas Sharlee A., Hackett Timothy B., Mazzaferro Elisa M. (2012): Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care, 22, 690-696 https://doi.org/10.1111/j.1476-4431.2012.00818.x
 
Miller L. K., Devi L. A. (): The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications. Pharmacological Reviews, 63, 461-470 https://doi.org/10.1124/pr.110.003491
 
Muccioli Giulio G. (2010): Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today, 15, 474-483 https://doi.org/10.1016/j.drudis.2010.03.007
 
Mukhopadhyay Partha, Bátkai Sándor, Rajesh Mohanraj, Czifra Nora, Harvey-White Judith, Haskó György, Zsengeller Zsuzsanna, Gerard Norma P., Liaudet Lucas, Kunos George, Pacher Pál (2007): Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. Journal of the American College of Cardiology, 50, 528-536 https://doi.org/10.1016/j.jacc.2007.03.057
 
Munro Sean, Thomas Kerrie L., Abu-Shaar Muna (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65 https://doi.org/10.1038/365061a0
 
Nagarkatti Prakash, Pandey Rupal, Rieder Sadiye Amcaoglu, Hegde Venkatesh L, Nagarkatti Mitzi (2009): Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1, 1333-1349 https://doi.org/10.4155/fmc.09.93
 
Nolen RS (2013): With pet owners already using the drug as medicine, veterinarians need to join the debate. Journal of the American Veterinary Medical Association 242, 1604–1609.
 
Pacher P. (2006): The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58, 389-462 https://doi.org/10.1124/pr.58.3.2
 
Parker Linda A., Kwiatkowska Magdalena, Burton Page, Mechoulam Raphael (2004): Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology, 171, 156-161 https://doi.org/10.1007/s00213-003-1571-2
 
Pascual David, Goicoechea Carlos, Suardíaz Margarita, Martín María Isabel (2005): A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain, 118, 23-34 https://doi.org/10.1016/j.pain.2005.07.008
 
Pate David W., Järvinen Kristiina, Urtti Arto, Mahadevan Vaidyanath, Järvinen Tomi (1998): Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sciences, 63, 2181-2188 https://doi.org/10.1016/S0024-3205(98)00499-8
 
Pertwee Roger G. (1997): Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74, 129-180 https://doi.org/10.1016/S0163-7258(97)82001-3
 
Pertwee Roger G. (2005): The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal, 7, E625-E654 https://doi.org/10.1208/aapsj070364
 
Pertwee Roger G (2009): Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156, 397-411 https://doi.org/10.1111/j.1476-5381.2008.00048.x
 
Pertwee Roger G. (2014): Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proceedings of the Nutrition Society, 73, 96-105 https://doi.org/10.1017/S0029665113003649
 
Porcella Anna, Maxia Chiara, Gessa Gian Luigi, Pani Luca (2001): The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. European Journal of Neuroscience, 13, 409-412 https://doi.org/10.1046/j.0953-816X.2000.01401.x
 
Porter A. C. (): Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020-1024 https://doi.org/10.1124/jpet.301.3.1020
 
Presley BC, Jansen-Varnum SA, Logan BK (2013): Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review 25, 27–46.
 
Re G., Barbero R., Miolo A., Di Marzo V. (2007): Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal, 173, 21-30 https://doi.org/10.1016/j.tvjl.2005.10.003
 
ROBSON P. (): Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry, 178, 107-115 https://doi.org/10.1192/bjp.178.2.107
 
Rog D. J., Nurmikko T. J., Friede T., Young C. A. (): Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812-819 https://doi.org/10.1212/01.wnl.0000176753.45410.8b
 
Ross Ruth A (2003): Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology, 140, 790-801 https://doi.org/10.1038/sj.bjp.0705467
 
Russo Ethan (2008): Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, Volume 4, 245-259 https://doi.org/10.2147/TCRM.S1928
 
Sarfaraz S., Adhami V. M., Syed D. N., Afaq F., Mukhtar H. (2008): Cannabinoids for Cancer Treatment: Progress and Promise. Cancer Research, 68, 339-342 https://doi.org/10.1158/0008-5472.CAN-07-2785
 
Scarampella F., Abramo F., Noli C. (2001): Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology, 12, 29-39 https://doi.org/10.1046/j.1365-3164.2001.00214.x
 
Scheen André J., Paquot Nicolas (2009): Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 103-116 https://doi.org/10.1016/j.beem.2008.09.001
 
Serpell M., Ratcliffe S., Hovorka J., Schofield M., Taylor L., Lauder H., Ehler E. (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain, 18, 999-1012 https://doi.org/10.1002/j.1532-2149.2013.00445.x
 
Slais K., Landa L., Sulcova A. (2003): P.5.023 The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/exploratory behaviour and body weight in mice. European Neuropsychopharmacology, 13, S417- https://doi.org/10.1016/S0924-977X(03)92272-3
 
Slavic Svetlana, Lauer Dilyara, Sommerfeld Manuela, Kemnitz Ulrich Rudolf, Grzesiak Aleksandra, Trappiel Manuela, Thöne-Reineke Christa, Baulmann Johannes, Paulis Ludovit, Kappert Kai, Kintscher Ulrich, Unger Thomas, Kaschina Elena (2013): Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 91, 811-823 https://doi.org/10.1007/s00109-013-1034-0
 
Song ZH, Slowey CA (2000): Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. Journal of Pharmacology and Experimental Therapeutics 292, 136–139.
 
Stanley CP, Hind WH, O’Sullivan SE (2013): Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology 75, 313–322.
 
Steffens Sabine, Pacher Pál (2012): Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. British Journal of Pharmacology, 167, 313-323 https://doi.org/10.1111/j.1476-5381.2012.02042.x
 
Steffens Sabine, Veillard Niels R., Arnaud Claire, Pelli Graziano, Burger Fabienne, Staub Christian, Zimmer Andreas, Frossard Jean-Louis, Mach François (2005): Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434, 782-786 https://doi.org/10.1038/nature03389
 
SVIZENSKA I, DUBOVY P, SULCOVA A (2008): Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90, 501-511 https://doi.org/10.1016/j.pbb.2008.05.010
 
Tallett Amy J., Blundell John E., Rodgers John R. (2007): Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behavioural Pharmacology, 18, 591-600 https://doi.org/10.1097/FBP.0b013e3282eff0a9
 
Unschuld PU (1986): Medicine in China. A History of Pharmaceutics. University of California Press, Berkeley and Los Angele. 167 pp.
 
Van Sickle Marja D., Oland Lorraine D., Mackie Ken, Davison Joseph S., Sharkey Keith A. (): Δ 9 -Tetrahydrocannabinol selectively acts on CB 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. American Journal of Physiology - Gastrointestinal and Liver Physiology, 285, G566-G576 https://doi.org/10.1152/ajpgi.00113.2003
 
Van Sickle M. D. (2005): Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 310, 329-332 https://doi.org/10.1126/science.1115740
 
Velasco Guillermo, Sánchez Cristina, Guzmán Manuel (): Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 12, 436-444 https://doi.org/10.1038/nrc3247
 
Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., Gallily R. (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39, 143-151 https://doi.org/10.1080/08916930500356674
 
Weiss Lola, Zeira Michael, Reich Shoshana, Slavin Shimon, Raz Itamar, Mechoulam Raphael, Gallily Ruth (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54, 244-249 https://doi.org/10.1016/j.neuropharm.2007.06.029
 
Xiong W., Cui T., Cheng K., Yang F., Chen S.-R., Willenbring D., Guan Y., Pan H.-L., Ren K., Xu Y., Zhang L. (): Cannabinoids suppress inflammatory and neuropathic pain by targeting  3 glycine receptors. Journal of Experimental Medicine, 209, 1121-1134 https://doi.org/10.1084/jem.20120242
 
Zuardi Antonio Waldo (2006): History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria, 28, 153-157 https://doi.org/10.1590/S1516-44462006000200015
 
Zubrzycki M, Liebold A, Janecka A, Zubrzycka M (2014): A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and Pharmacology 65, 171–181.
 
download PDF

© 2019 Czech Academy of Agricultural Sciences